15 results
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
Disease, PRES Pathophysiology ... Puncture, EEG Treatment ... Erythematosus #SLE #CNS #neurology ... #rheumatology # ... diagnosis #management #treatment
Conversion - Epoetin alfa (Procrit®) to Darbepoetin alfa (Aranesp™)

#Epoetin #Darbepoetin #Erythropoietin #Conversion #Table #ESAs #Procrit #Aranesp
Erythropoietin #Conversion #Table ... Procrit #Aranesp #Pharmacology ... #Hematology #Nephrology
Management of Lupus Nephritis
Lupus nephritis (LN) in 10 to 40% of SLE
Hallmark = proteinuria 20.5 g/g
Management of Lupus ... Nephritis Lupus ... Nephritis #Management #treatment ... #management #rheumatology ... #nephrology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
Drug Induced Lupus ... constitutional symptoms • Treatment ... life-threatening • Treatment ... sle #comparison #table ... #rheumatology #
Pharmacotherapy for Migraine Prophylaxis 

Who is indicated for migraine prophylaxis? Patients who experience more than 3
appropriate acute treatment ... #Medications #Table ... #Pharmacology # ... Management #Neurology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
management #algorithm #pharmacology ... #treatment #medications ... #table #pharmacotherapy ... decisionaid #cardiology #hematology
Migraine Treatment Overview

 • What is a Migraine?
 • Pathophysiology
 • Common Migraine Triggers
 • Diagnosis
Migraine Treatment ... • Pathophysiology ... Prophylactic Treatment ... #management #pharmacology ... #prophylaxis #neurology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
blood donor • Pathophysiology ... : 33% • Treatment ... transfusion • Pathophysiology ... : No • Treatment ... diagnosis #comparison #table
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... Chemotherapy #Oncology #Hematology ... #Interactions #Table ... #Pharmacology
Potassium Binders for Management of Hyperkalemia
 • SPS - Sodium polystyrene sulfonate
 • Patiromer (veltassa)
 •
#Hyperkalemia #treatment ... #pharmacology # ... table #comparison ... #nephrology